Allegro, Senju to collaborate on integrin peptide therapy in Japan

Senju Pharmaceutical will co-develop and market Allegro Ophthalmics’ integrin peptide therapy in Japan under an agreement between the two companies, according to a joint news release. The first-in-class therapy targets integrin with an oligopeptide to reduce leakage from and growth of aberrant blood vessels. It is intended for use as an intravitreal injection in patients with vascular eye diseases, including diabetic macular edema and wet age-related macular degeneration, the release said.

Full Story →